Validation of Indications for Surgery of European Evidence-Based Guidelines for Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms
Which patients with pancreatic intraductal papillary mucinous neoplasms (IPMNs) should undergo surgical intervention remains a controversial issue. The aim of this retrospective study was to validate the new European evidence-based guidelines on pancreatic cystic neoplasms (EEBGPCN) for the management of IPMNs.
One hundred fifty-eight patients with resected IPMNs at National Taiwan University Hospital between January 1994 and December 2016 were enrolled. Clinical information, including new-onset diabetes mellitus (DM) and preoperative CA 19-9 levels, were collected. All patients were stratified into three groups—absolute, relative indications, and conservative approach—according to EEBGPCN. The performance characteristics of EEBGPCN for high-grade dysplasia (HGD)/invasive carcinoma (IC) of IPMNs were calculated.
One hundred seven (67.7%) patients with low-grade dysplasia and 51 patients with HGD/IC, including 10 HGD and 41 IC, were analyzed. The missed rate for HGD/IC by EEBGPCN was 1.9% (3/158). The sensitivity, specificity, positive and negative predictive values, and accuracy of the absolute or relative indications for resecting IPMN according to EEBGPCN were 94.1%, 28.0%, 38.4%, 90.9%, and 49.4%. Jaundice, enhancing mural nodule < 5 mm, cyst diameter > 40 mm, increased levels of serum CA 19-9, new-onset DM, and main pancreatic duct dilation were associated with HGD/IC.
The missed rate for HGD/IC is low by EEBGPCN. Increased serum CA 19-9 and new-onset DM in EEBGPCN were verified as the indications for the surgical resection of IPMNs.
KeywordsIntraductal papillary mucinous neoplasms (IPMNs) New-onset diabetes mellitus (DM) European evidence-based guidelines
I-Shiow Jan: contributions to the design of study, interpretation of data, and drafting the manuscript. Ming-Chu Chang, Ching-Yao Yang, Yu-Wen Tien, Yung-Ming Jeng, Chih-Horng Wu, and Bang-Bin Chen: contributions to acquisition, analysis, and interpretation of data and assisting in drafting the manuscript. Yu-Ting Chang: contributions to the design of the study, acquisition, analysis, and interpretation of data, drafting the manuscript, and final approval of the version to be published.
- 2.Xu MM, Yin S, Siddiqui AA, Salem RR, Schrope B, Sethi A et al. Comparison of the diagnostic accuracy of three current guidelines for the evaluation of asymptomatic pancreatic cystic neoplasms. Medicine (Baltimore). 2017;96(35):e7900. https://doi.org/10.1097/md.0000000000007900.CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Hsiao CY, Yang CY, Wu JM, Kuo TC, Tien YW. Utility of the 2006 Sendai and 2012 Fukuoka guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas: A single-center experience with 138 surgically treated patients. Medicine (Baltimore). 2016;95(38):e4922. https://doi.org/10.1097/md.0000000000004922.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.M. H, L. B, U. H, T. P, C. T, J. K et al. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789-804. https://doi.org/10.1136/gutjnl-2018-316027.
- 11.Basturk O, Hong SM, Wood LD, Adsay NV, Albores-Saavedra J, Biankin AV et al. A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol. 2015;39(12):1730-41. https://doi.org/10.1097/pas.0000000000000533.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Yu S, Takasu N, Watanabe T, Fukumoto T, Okazaki S, Tezuka K et al. Validation of the 2012 Fukuoka Consensus Guideline for Intraductal Papillary Mucinous Neoplasm of the Pancreas From a Single Institution Experience. Pancreas. 2017;46(7):936-42. https://doi.org/10.1097/mpa.0000000000000874.CrossRefPubMedGoogle Scholar
- 14.Srinivasan N, Teo J-Y, Chin Y-K, Hennedige T, Tan DM, Low AS et al. Systematic review of the clinical utility and validity of the Sendai and Fukuoka Consensus Guidelines for the management of intraductal papillary mucinous neoplasms of the pancreas. HPB (Oxford). 2018;20(6):497-504. https://doi.org/10.1016/j.hpb.2018.01.009.CrossRefGoogle Scholar
- 15.Zhou W, Xu Y, Rong Y, Wu W, Kuang T, Xin B et al. Validation of Sendai and Fukuoka consensus guidelines in predicting malignancy in patients with preoperatively diagnosed mucinous pancreatic cystic neoplasms. J Surg Oncol. 2017;117(3):409-16. https://doi.org/10.1002/jso.24882.CrossRefPubMedGoogle Scholar
- 16.Wong J, Weber JA Centeno B, Vignesh S, Harris CL, Klapman JB et al. High-Grade Dysplasia and Adenocarcinoma Are Frequent in Side-Branch Intraductal Papillary Mucinous Neoplasm Measuring Less than 3 cm on Endoscopic Ultrasound. J Gastrointest Surg. 2013;17(1):78-85. https://doi.org/10.1007/s11605-012-2017-0.CrossRefPubMedGoogle Scholar
- 20.Pannala R, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M et al. Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol. 2009;104(9):2318-25. https://doi.org/10.1038/ajg.2009.253.CrossRefPubMedPubMedCentralGoogle Scholar